Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

CANCER drug co. Oxford Biomedica charts (OXB)     

apple - 25 Mar 2004 20:47

Chart.aspx?Provider=EODIntra&Code=OXB&Sidraw?scheme=Colourful&size=Medium&showVodraw?scheme=Colourful&showVolume=true&stdraw?scheme=Colourful&size=Medium&showVoChart.aspx?Provider=EODIntra&Code=OXB&SiChart.aspx?Provider=EODIntra&Code=OXB&Sidraw?scheme=Designer&size=Big&showVolumedraw?scheme=Designer&size=Big&showVolume


OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021


MUNI - 12 Feb 2008 12:12 - 1090 of 1451

COMPANIES - INTERNATIONAL: Sanofi hopes lift Oxford
By Salamander Davoudi in London, Financial Times
Published: Feb 12, 2008


Oxford BioMedica shares jumped 17 per cent yesterday on the back of speculation that the UK biotechnology company is about to be bought by Sanofi Aventis, its French partner.

Both Sanofi and Oxford BioMedica declined to comment.

Analysts believe any offer for the company would - at its lowest - be about the 50p level, valuing the business at about 280m ($546m). This is less than the 518m ($751m) Sanofi could have to pay the biotech company under the terms of a licensing deal for TroVax, a cancer vaccine being developed for renal, prostate and colorectal cancer.

Navid Malik, an analyst at Collins Stewart, said: "Sanofi Aventis has committed about 350m and if everything is successful they are never going to pay this when the company is so cheap at the moment."

Shares in the company have fallen more than 60 per cent in the past six months. Analysts believe Sanofi Aventis could be waiting for a final safety review for TroVax, due in the next few months.

Paul Cuddon, an analyst at KBC Peel Hunt, said: "There may have to be a data trigger, they may be waiting for the final TroVax safety review before they do a deal and this is coming fairly soon."

Oxford BioMedica is also expecting phase I/II data for ProSavin, its gene-based therapy for Parkinson's disease this year. Phase Three data for Trovax will not be known until 2009.

A deal between the two companies has long been expected. Sanofi's cancer products are ageing. Acomplia, its new obesity treatment, has blockbuster potential but has been delayed by US regulators, while Plavix, its blood thinner, faces generic competition.

Shares in Oxford BioMedica rose 3p to 22p.

hangon - 12 Feb 2008 17:33 - 1091 of 1451

Driver, I think you are right, but those that bought below 20p will sell into this ungainly rush - they will make a few bob and those that are still buying (now), will wish they'd waited. Interesting that FT couldn't get anything out of the two companies - surely a denial is overdue? . . . but it is only two days ( following a poorly researched Rumour from the Mail on Sunday ( I think- DYOR).
Anyone that follows OXB would be very surprised - for the reasons I put forward already.
I suppose the FT has to report the sp movements; even though it's tailing off, now. Probably by Friday we shall know What's What.
The Trovax conclusion isn't expected until earliest =end-2008.
I hold.

Toya - 12 Feb 2008 19:51 - 1092 of 1451

Hangon: as soon as an RNS is published about a possible offer, the sp will shoot up - literally within seconds. Judging from the huge volume of trades in the past couple of days, compared with normal, I reckon something could be behind these rumours.

Toya - 12 Feb 2008 19:53 - 1093 of 1451

Thanks for the various articles posted above. I came across this today, from a US site:

Oxford Biomedica Shares Surge On Takeover Speculation - from cnn.com

hangon - 13 Feb 2008 11:25 - 1094 of 1451

Toya it* is the same news, following a silly article this weekend, as already posted. and it's confused as it mentions 50p would save Sanofi money then quotes a UK Broker suggesting 70p is their target - so Sanofi would need to bid 40% more than 50p - it would save them very little and increase their Risk. They have a partnership and presumably are/were happy with the risk/reward.

Furthermore, it's part-way through the third day and sill NO official RNS -


Today the sp is static at 27p -

Repeatedly posting/reading the same news is not "evidence" - it is still possible there will be a Bid - it's a free Market, but OXB has always been pretty good at keeping its secrets - for example the deal with Sanofi last summer was a bolt from the blue.
Of course, shares were higher then, so no sp-rash because the RNS spelled it like it was - cash up-front and a partnership.
Now we are playing the long-game, hoping the PhIII trials are satisfactory and anticipating good news by the end of 2008. But this is far from certain as additional Trials may be added by OXB ( to secure a better final deal?) - OR the Regulator should something go wrong ( Grief, hope-not!).

The only information we need "now" is something from OXB itself, via RNS.

Everything else is hot air - either way - let's look at the facts: There is no RNS supporting this sp rise. Not yet at least, now wait for me to be proved wrong - but as a holder 50p would be very nice after so many years. Even 40p would tempt me to sell, since Cash is King right now.
PS.I've done nicely with Woolworths - all we need now is some action in the shops!

*that link will switch you out of MoneyAM - you need a separate "window" -

Toya - 13 Feb 2008 16:27 - 1095 of 1451

Hangon: the link is as set up by MoneyAM - it doesn't appear in a separate window: when you've clicked and read simply click the back arrow to take you right back to this page.

Toya - 13 Feb 2008 16:32 - 1096 of 1451

Also: last summer's deal was not a surprise to anyone who had been following the company. The way these drugs are developed is usually with a big pharmaco. See link below (and then back-arrow to bring you back here!) - there had been talks going on for months to secure a co-developer.

Article of November 2006 signalling in talks re Trovax deal

cynic - 14 Feb 2008 09:52 - 1097 of 1451

strange stuff again this morning ..... trades show almost no buys and a preponderance of AT sales ..... with sp now down 2p, perhaps a time to buy, though for myself, i have enough

hangon - 14 Feb 2008 13:27 - 1098 of 1451

Toya - I agree it was no surprise ( Sanofi-2007) . .. but the details/amount were out of the blue - there were no "rumours" as such - hence my feeling that what we witnessed this week was manipulation.
Shares gives OXB a "buy" at 18p ( can't argue at that level, although less would be better), and still the sp falls -
-rather confirms my view....or....

cynic - 14 Feb 2008 13:30 - 1099 of 1451

would be very interesting to know the performance of ALL shares recommended either as buys or sells over say a 12 month period .... always worth reading about, but the mag has to write about something every week

driver - 14 Feb 2008 16:39 - 1100 of 1451

Just a bit of profit taking by the looks of it those that bought in at 18p-ish before the next hike in the sp. 50p looks on the cards.

Toya - 14 Feb 2008 18:25 - 1101 of 1451

I reckon it's possible. A number of large Buys came in near the end of the day, which is possibly encouraging

cynic - 14 Feb 2008 21:56 - 1102 of 1451

but with Dow down quite heavily and with London to follow suit,
it's possible that it's possibly not encouraging at all - lol!

queen1 - 15 Feb 2008 09:40 - 1103 of 1451

Somebody likes OXB:

Oxford Biomedica said Cubana Investments bought 30.59 mln shares in the company representing 5.70 pct stake of the total voting rights. Speculations are rife that the gene therapy company is in a bid situation with media reports saying French pharmaceutical giant Sanofi-Aventis might be looking to acquire it.

cynic - 15 Feb 2008 11:15 - 1104 of 1451

not exactly new news, but in a very dodgy market OXB is doing just fine and am happy to stay put rather than cash in the profit as i have with several other stocks this morning and yesterday

transco15 - 17 Feb 2008 07:54 - 1105 of 1451

Well I purchased before christmas on a hunch..... good hunch takeover imminent!

MIDAS7576 - 17 Feb 2008 12:45 - 1106 of 1451

Don`t be short chaps !

hahn - 18 Feb 2008 18:24 - 1107 of 1451

Looks like OXB is on the move again. Will we see 30p target this week. Chart
looking good. Rise above 27p is encouraging. Any comment on this current movement is welcomed..

hangon - 19 Feb 2008 16:28 - 1108 of 1451

There's now some feel-good in the Matrket, following rumours that UK Banks are the increase their Div (really?), but that's a rumour - as is the Sanofi takeover right now before Results are out...
Anyone else?

queen1 - 19 Feb 2008 19:41 - 1109 of 1451

Not a rumour - Barclays increased its full-year payout today.
Register now or login to post to this thread.